Literature DB >> 11135451

Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus.

J F Ghersi-Egea1, N Strazielle.   

Abstract

The choroid plexuses (CPs) have the capability to modulate drug delivery to the cerebrospinal fluid (CSF) and to participate in the overall cerebral biodisposition of drugs. The specific morphological properties of the choroidal epithelium and the existence of a CSF pathway for drug distribution to different targets in the central nervous system suggest that the CP-CSF route is more significant than previously thought for brain drug delivery. In contrast to its role in CSF penetration of drugs, CP is also involved in brain protection in that it has the capacity to clear the CSF from numerous potentially harmful CSF-borne exogenous and endogenous organic compounds into the blood. Furthermore, CP harbors a large panel of drug-metabolizing enzymes as well as transport proteins of the multidrug resistance phenotype, which modulate the cerebral bioavailability of drugs and toxins. The use of an in vitro model of the choroidal epithelium suitable for drug transport studies has allowed the demonstration of the choroidal epithelium acting as an effective metabolic blood-CSF barrier toward some xenobiotics, and that a vectorial, blood-facing efflux of conjugated metabolites occurs at the choroidal epithelium. This efflux involves a specific transporter with characteristics similar to those of the multidrug resistance associated protein (MRP) family members. Indeed, at least one member, MRP1, is largely expressed at the CP epithelium, and localizes at the basolateral membrane. These metabolic and transport features of the choroidal epithelium point out the CP as a major detoxification site within the brain. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11135451     DOI: 10.1002/1097-0029(20010101)52:1<83::AID-JEMT10>3.0.CO;2-N

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  30 in total

Review 1.  Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

Authors:  Elizabeth C M de Lange; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Bilirubin, a curse and a boon.

Authors:  J D Ostrow; C Tiribelli
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

Review 3.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 4.  Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route.

Authors:  Conrad E Johanson; John A Duncan; Edward G Stopa; Andrew Baird
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

Review 5.  Treatment of spinal cord injury by transplantation of cells via cerebrospinal fluid.

Authors:  Yan Liu; Hong-Yun Huang
Journal:  Neurosci Bull       Date:  2008-10       Impact factor: 5.203

Review 6.  Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases.

Authors:  Chaitali Ghosh; Vikram Puvenna; Jorge Gonzalez-Martinez; Damir Janigro; Nicola Marchi
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

7.  Cerebrospinal fluid and plasma propofol concentration during total intravenous anaesthesia of patients undergoing elective intracranial tumor removal.

Authors:  Wei Luo; Yu-Hong Li; Jian-Jun Yang; Jie Tian; Jian-Guo Xu
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

8.  Free and bound propofol concentrations in human cerebrospinal fluid.

Authors:  Andrzej L Dawidowicz; Rafal Kalitynski; Anna Fijalkowska
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

9.  Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.

Authors:  Markos Leggas; Masashi Adachi; George L Scheffer; Daxi Sun; Peter Wielinga; Guoqing Du; Kelly E Mercer; Yanli Zhuang; John C Panetta; Brad Johnston; Rik J Scheper; Clinton F Stewart; John D Schuetz
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

Review 10.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.